Dose-reduced (** This applies to virtually all cancer medications including chemotherapy agents (carboplatin, paclitaxel, doxorubicin), targeted therapies (trastuzumab, imatinib), and immunotherapy drugs (pembrolizumab, nivolumab) - any brand name cancer drug may be do)
Otras Medicaciones
Description
The use of dose-reduced chemotherapy or targeted therapies in colorectal cancer (CRC) is often tailored to individual patient tolerance and toxicity profiles. These agents may be used across various lines of therapy, including adjuvant settings after surgery, as part of first-line regimens for metastatic disease, or in later lines when initial treatments are no longer effective.
Mechanism of Action
The mechanism of action varies widely depending on the specific drug and its pharmacological category; for example, chemotherapy drugs like carboplatin inhibit DNA synthesis and repair in rapidly dividing cells, while targeted therapies such as trastuzumab block HER2 receptors to prevent cancer cell proliferation.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.